{"organizations": [], "uuid": "50912b40ff8f567f96084f63364777f30d6e410e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aurobindo-pharma-says-us-fda-issue/brief-aurobindo-pharma-says-u-s-fda-issued-form-483-with-9-observations-for-cos-unit-idUSFWN1QN05X", "country": "US", "domain_rank": 408, "title": "BRIEF-Aurobindo Pharma Says U.S. FDA Issued Form 483 With 9 Observations for Co's Unit", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.947, "site_type": "news", "published": "2018-03-05T15:37:00.000+02:00", "replies_count": 0, "uuid": "50912b40ff8f567f96084f63364777f30d6e410e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aurobindo-pharma-says-us-fda-issue/brief-aurobindo-pharma-says-u-s-fda-issued-form-483-with-9-observations-for-cos-unit-idUSFWN1QN05X", "ord_in_thread": 0, "title": "BRIEF-Aurobindo Pharma Says U.S. FDA Issued Form 483 With 9 Observations for Co's Unit", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "hyderabad", "sentiment": "none"}, {"name": "co", "sentiment": "none"}], "organizations": [{"name": "brief-aurobindo pharma says u.s. fda", "sentiment": "negative"}, {"name": "observations for co", "sentiment": "negative"}, {"name": "reuters) - aurobindo pharma ltd", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Aurobindo Pharma Ltd:\n* AUROBINDO PHARMA LTD CLARIFIES ON NEWS ITEM ON COâ€™S UNIT 4 GETTING 9 OBSERVATIONS AFTER U.S. FDA INSPECTION\n* U.S. FDA CONDUCTED INSPECTION AT UNIT IV, HYDERABAD; AT END OF INSPECTION, CO WAS ISSUED FORM 483 WITH 9 OBSERVATIONS\n* CO WOULD BE REPLYING TO FDA WITHIN 15 WORKING DAYS Source text - bit.ly/2CZTzED Further company coverage:\n ", "external_links": ["http://bit.ly/2CZTzED", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T15:37:00.000+02:00", "crawled": "2018-03-06T22:33:08.004+02:00", "highlightTitle": ""}